A subset of bone cancer patients may respond to IGF1R inhibitors based on their genetic profile A subgroup of patients with osteosarcoma — a form of bone cancer — could be helped by an existing drug, suggest scientists from the Wellcome Trust Sanger Institute and their collaborators at University College London Cancer Institute and the...
Category: <span>Cancer</span>
Post
Researchers Uncover What Causes Cancer Cells to Spread and How We Can Slow It
IN BRIEF Johns Hopkins University researchers identified a key mechanism behind one of cancer’s deadliest traits. By understanding how metastasis works, their study presents new possibilities for preventing the spread of cancer in the body. UNDERSTANDING CANCER CELLS Treating cancer can be tricky: for one, cancer cells tend to spread quickly, known as metastasis — a...
Post
Drug, herb interactions frequent for cancer patients
Allan Ramos-Esquivel, M.D., from Hospital San Juan de Dios in San José Costa Rica, and colleagues administered a questionnaire to patients starting a new anticancer therapy to identify concomitant use of any over-the-counter drug or herbal supplement. The authors examined clinically relevant DDIs and HDIs among 149 patients. If the clinical pharmacist recognized a potentially clinically relevant DDI,...
Post
Immunotherapy kinder than chemotherapy for patients with head and neck cancer
The immunotherapy nivolumab is kinder than chemotherapy for people with advanced head and neck cancer – easing many of the negative effects of the disease on patients’ quality of life. Both head and neck cancer and the treatment for it can have a huge impact on patients – affecting their speech, breathing, eating and drinking,...
Post
A Unique Amino Acid for Brain Cancer Therapy
Photodynamic therapy is often used to treat brain tumors because of its specificity—it can target very small regions containing cancerous cells while sparing the normal cells around it from damage. It works by injecting a drug called a photosensitizer into the bloodstream, where it gathers in cells, and then exposing the drug-filled cells to light....
Post
AstraZeneca’s Lynparza Could Be Transformed Into Precision Medicine For Prostate Cancer
Thanks to a new three-in-one blood test, AstraZeneca’s drug Lynparza could be transformed into precision medicine for patients with prostate cancer, researchers said. On Monday, June 19, a newly published study revealed how a blood test that analyzes cancer DNA from patients can revolutionize prostate cancer treatment. AstraZeneca’s Lynparza has long been approved for the treatment...
Post
DIY test set to let thousands escape colonoscopy ordeal: Patients will be given kits by GPs to avoid invasive hospital procedure, say doctors
GPs will give DIY kits to NHS patients with bleeding and lower abdominal pain Currently people with those symptoms are referred for colonoscopies Four per cent of 260,000 Britons sent for examination in 2017 had bowel cancer A DIY test that can detect the early signs of bowel cancer could save thousands of Britons from...
Post
Study shows how an opportunistic microbe kills cancer cells
Electron microscopic image of a single human lymphocyte. New study results show for the first time how dying cells ensure that they will be replaced, and suggests an ingenious, related new approach to shrinking cancerous tumors. A research team from Rush University Medical Center will publish a new paper this week in the journal Developmental...
Post
Groups of Nanoparticles Powered by a Magnet Team Up to Kill Cancer Cells
Number of ways have been developed that allow nanoparticles to kill cancer cells. Some of these include delivering chemo agents, converting electromagnetic energy beamed into heat, and manipulating with the signaling processes of tumor cells. An international team of researchers is now reporting in journal Theranostics a way of bunching iron oxide particles doped with zinc around tumors and then...
Post
Experimental drug shows promise
A collaboration between Saïd M. Sebti, Ph.D., chair of Moffitt Cancer Center’s Drug Discovery Department, and Michele Pagano, M.D., chair of the Department of Biochemistry and Molecular Pharmacology at New York University’s Langone Medical Center, led to the publication of an important study in the latest issue of Nature. The investigation found that the drug, geranylgeranyltransferase...